SCHEMBL251676

SCHEMBL251676

Cc1cc2cc(C(C)N3C(=O)c4ccccc4C3=O)c(Cl)nc2s1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.38
NPSR1 Q6W5P4 2/20 0.38
NPY1R P25929 1/20 0.38
NPY2R P49146 1/20 0.38
LMNA P02545 2/20 0.35
USP2 O75604 1/20 0.35
TSHR P16473 1/20 0.35
MAPT P10636 3/20 0.34
TDP1 Q9NUW8 1/20 0.33
KDM4E B2RXH2 2/20 0.33
NPC1 O15118 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
ALDH1A1 P00352 3/20 0.32
TP53 P04637 2/20 0.32
HTT P42858 1/20 0.32
MAPK1 P28482 1/20 0.32
KMT2A Q03164 1/20 0.32
POLB P06746 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL251675 1.00 HPGD (0.38) HPGDNPSR1NPY1RNPY2RLMNA
SCHEMBL252620 0.89 LMNA (0.36) HPGDNPSR1NPY1RNPY2RLMNA
SCHEMBL252619 0.89 LMNA (0.36) HPGDNPSR1NPY1RNPY2RLMNA
SCHEMBL248918 0.87 NPSR1 (0.35) HPGDNPSR1NPY1RNPY2RLMNA
SCHEMBL251819 0.87 NPSR1 (0.35) HPGDNPSR1NPY1RNPY2RLMNA
SCHEMBL252434 0.81 LMNA (0.36) HPGDNPSR1NPY1RNPY2RLMNA
SCHEMBL252433 0.81 LMNA (0.36) HPGDNPSR1NPY1RNPY2RLMNA
SCHEMBL252459 0.80 IDO1 (0.38) HPGDNPSR1NPY1RNPY2RLMNA
SCHEMBL246126 0.80 IDO1 (0.38) HPGDNPSR1NPY1RNPY2RLMNA
SCHEMBL14870378 0.78 EGFR (0.42) LMNAUSP2TSHRMAPTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8759371-B2 Heterocyclic compounds and their uses AMGEN INC. (US) 2014-06-24 US disclosed
EP-2588468-B1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY AMGEN INC (US) 2014-03-26 EP disclosed
EP-2588468-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY Amgen Inc. (US) 2013-05-08 EP disclosed
US-20130085151-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC (US) 2013-04-04 US disclosed
WO-2012003262-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY AMGEN INC. (US) 2012-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130085151-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES MCL1, MALT1, BCL9 HPGD 2211/4885NPSR1 2664/4885NPY1R 4479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.